Schering-Plough

Schering-Plough Corp. has made leadership and organizational changes at Schering-Plough Research Institute (SPRI), the R&D arm of the company.
   
Jacqueline Elbonne, Ph.D., has been named vice president, global research quality, SPRI. Dr. Elbonne will build and lead a worldwide research quality team overseeing all SPRI activities governed by cGMP, GLP, GCP and Good Pharmacovigilance Practices (GPP). She will also direct the design, implementation and performance management of global research quality management systems to meet regulatory requirements worldwide. She will report to Thomas P. Koestler, Ph.D., executive vice president and president of SPRI, with shared accountability for SPRI quality systems to Richard S. Bowles III, senior vice president, global quality operations.
   
Dr. Elbonne joined the company in 2000 and has held various positions of increasing responsibility in SPRI, analytical development and global quality. She recently served as vice president, pharmaceutical sciences quality, overseeing global clinical manufacturing operations, which included meeting all commitments under the U.S. consent decree.  
   
Also, two positions were created as a result of the expanded product portfolio following the acquisition of Organon BioSciences. Martin H. Huber, Jr., M.D., and Hans Rekers, M.D., will report to Robert J. Spiegel, M.D., chief medical officer and senior vice president. Dr. Huber was appointed vice president, global pharmacovigilance, and deputy chief medical officer. He will continue his current responsibilities and will also serve on Schering-Plough’s safety review board. He will  work on product-related issues with health authorities and professional societies, manage medical aspects of litigation issues and work with medical directors from country operations on risk management and product-specific issues.
   
Dr. Huber has served as vice president, global pharmacovigilance, since joining the company in July 2006. He has played a key role in the development of a globally aligned organization for global pharmacovigilance as part of Schering-Plough’s global clinical harmonization program and on the design and rollout of a computerized system for the collection, tracking and reporting of drug safety information.  
   
Dr. Rekers was appointed deputy chief medical officer for Europe. In this role, he will continue his current responsibilities and will serve on Schering-Plough’s safety review board and on the company’s PReP (preparedness response) team. He will also work on product-related issues with worldwide health authorities and professional societies, manage medical aspects of litigation issues and work with medical directors from country operations on risk management and product-specific issues.
   
Dr. Rekers has been with Organon International for the past 20 years serving in a range of positions of increasing responsibility, most recently as vice president, medical affairs.